Galcanezumab in migraine prevention: a systematic review and meta-analysis of randomized controlled trials

BACKGROUND: Galcanezumab, along with three other monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway, represents the latest disease-specific and mechanism-based treatment for the prophylaxis of migraine. Galcanezumab shares data also for the prophylaxis of cluster head...

Descripción completa

Detalles Bibliográficos
Autores principales: Gklinos, Panagiotis, Mitsikostas, Dimos D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222235/
https://www.ncbi.nlm.nih.gov/pubmed/32426040
http://dx.doi.org/10.1177/1756286420918088

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222235/
https://www.ncbi.nlm.nih.gov/pubmed/32426040
http://dx.doi.org/10.1177/1756286420918088

Ejemplares similares